## National Vaccine Plan: From Strategy to Implementation

National Vaccine Advisory Committee Meeting June 15, 2011

Bruce Gellin, MD, MPH
Director, National Vaccine Program Office
Deputy Assistant Secretary for Health
Office of the Assistant Secretary for Health
Department of Health and Human Services





### Title XXI Public Health Service Act National Vaccine Program Responsibilities:

- Vaccine Research
- Vaccine Development
- Safety and efficacy testing of vaccines
- Licensing of vaccine manufacturers and vaccines
- Production and procurement of vaccines
- Distribution and use of vaccines
- Evaluating the need for, the effectiveness, and adverse effects of vaccines and immunization activities
- Coordinating governmental and nongovernmental activities
- Funding of federal agencies





### **2010 National Vaccine Plan Goals**

- 1. Develop new and improved vaccines
- 2. Enhance the vaccine safety system
- 3. Support communications to enhance informed vaccine decision-making
- 4. Ensure a stable supply of recommended vaccines and achieve better use of existing vaccines to prevent disease, disability and death in the United States
- Increase global prevention of death and disease through safe and effective vaccination





### National Vaccine Plan: Priorities for Implementation

A.	Develop a catalogue of priority vaccine targets of domestic and global health importance (Goal 1).
B.	Strengthen the science base for the development and licensure of new vaccines (Goals 1 and 2).
C.	Enhance timely detection and verification of vaccine safety signals and develop a vaccine safety scientific agenda (Goal 2).
D.	Increase awareness of vaccines, vaccine-preventable diseases, and the benefits/risks of immunization among the public, providers, and other stakeholders (Goal 3).
E.	Use evidence-based science to enhance vaccine-preventable disease surveillance, measurement of vaccine coverage, and measurement of vaccine effectiveness (Goal 4).
F.	Eliminate financial barriers for providers and consumers to facilitate access to routinely recommended vaccines (Goal 4).
G.	Create an adequate and stable supply of routinely recommended vaccines and vaccines for public health preparedness (Goal 4).
Н.	Increase and improve the use of interoperable health information technology and electronic health records (Goal 4).
l.	Improve global surveillance for vaccine-preventable diseases and strengthen global health information systems to monitor vaccine coverage, effectiveness, and safety (Goal 5).
J.	Support global introduction and availability of new and under-utilized vaccines to prevent diseases of public health importance (Goal 5).

### **Priorities**

- Develop a catalogue of priority vaccine targets of domestic and global health importance.
- Strengthen the science base for the development and licensure of new vaccines.
- Enhance timely detection and verification of vaccine safety signals and develop a vaccine safety research agenda.
- Increase awareness of vaccines, vaccinepreventable diseases, and the benefits/risks of immunization.
- Use evidence-based science to enhance vaccine-preventable disease surveillance, measurement of vaccine coverage, and measurement of vaccine effectiveness.





### **Priorities continued**

- Eliminate financial barriers for providers and consumers to facilitate access to routinely recommended vaccines.
- Create an adequate and stable supply of routinely recommended vaccines and vaccines for public health preparedness.
- Increase and improve the use of interoperable health information technology and electronic health records.
- Improve global surveillance for vaccinepreventable diseases and strengthen global health information systems to monitor vaccine coverage, effectiveness, and safety.
- Support global introduction and availability of mew and under-utilized vaccines.

### **Implementation Plan**

- Complement the National Vaccine Plan
- Develop during 2011
- Address priorities identified in the NVP
- Identify barriers to achieving priority
- Develop indicators for measuring progress
- Involve stakeholders 10 meeting being planned with guidance from HHS, RHAs, ASTHO and NACCHO






### Implementation in progress

- IOM Committee for Vaccine Prioritization
- Vaccines.gov
- "Confidence"/Vaccine hesitancy
- Public health financing/reimbursement
- Adult immunization/role of pharmacists
- Maternal Immunization
- Vaccine safety research agenda





## Setting Priorities for Vaccine Development







A TOOL FOR DECISIONMAKING

Kathleen R. Stratton, Jane S. Durch, and Robert S. Lawrence, Editors

Committee to Study Priorities for Vaccine Development
Division of Health Promotion and Disease Prevention
INSTITUTE OF MEDICINE

NATIONAL ACADEMY PRESS Washington, D.C.





### IOM Committee on Identifying and Prioritizing New Preventive Vaccines

- Charge: Develop an evidence-based approach and methodology for identifying and prioritizing the needs for developing new preventive vaccines of domestic and global importance.
- Considerations:
  - International and domestic priorities
  - Burden of illness and costs
  - Scientific opportunities and platform technologies
  - Stakeholder perspectives







## Goal 3: Support Communications to enhance informed decision-making



- Launched March 31
- Single-subject consumer website addressing vaccines, VPDs, and tools to learn critical behavioral info
- Partners: HHS-wide (CDC, FDA, NIH, HRSA) with support from VA and DoD





### Message Models






by

needs

Content driven by partners/consumer news











### Measuring Confidence







#### Measuring Confidence: Consumer Confidence Survey

The Consumer Confidence Survey® reflects prevailing business conditions and likely developments for the months ahead. This monthly report details consumer attitudes and buying intentions, with data available by age, income, and region.

The Index is calculated each month on the basis of a household survey of consumers' opinions on current conditions and future expectations of the economy. Opinions on current conditions make up 40% of the index, with expectations of future conditions comprising the remaining 60%.







Each month The Conference Board surveys 5,000 U.S. households.

The survey consists of five questions that ask the respondents' opinions about the following:

- Current business conditions
- Business conditions for the next six months
- Current employment conditions
- Employment conditions for the next six months
- Total family income for the next six months





# The Conference Board Consumer Confidence Index® Declines 31 May 2011

- The Conference Board Consumer Confidence
   Index®, which had improved in April,
   decreased in May.
- The Consumer Confidence Index now stands at 60.8 (1985=100), down from 66.0 in April.





#### **Vaccine Hesitancy**

- May 13<sup>th</sup> brainstorming discussion with a diverse group (communications, risk communications, behavioral economics, social marketing, consumer advertising, cultural anthropology, new media) about the issue of vaccine hesitancy
- Co-organized by NVPO, CDC, Partnership for Prevention, and ASTHO
- Purpose: Hear view of those outside of the immunization community on the root causes of the issue and consider approaches to improve communications efforts around the topic of vaccine hesitancy.
- Three key meeting insights include:
  - Action now is warranted and preferable to status quo
  - An effective strategic response framework to vaccine hesitancy will be one that is comprehensive and sustained.
  - · Issue requires a multi-disciplinary and multi-sector approach
- Next steps: key informant interviews and stakeholder discussions, gap analysis, development of a strategic plan and convening an advisory group to review the draft strategic framework and plan.







October 9, 2008


# Effectiveness of Maternal Influenza Immunization in Mothers and Infants

K. Zaman, M.B., B.S., Ph.D., Eliza Roy, M.B., B.S., D.C.H., Shams E. Arifeen, M.B., B.S., Dr.P.H., Mahbubur Rahman, M.B., B.S., Ph.D., Rubhana Raqib, Ph.D., Emily Wilson, M.H.S., Saad B. Omer, M.B., B.S., Ph.D., Nigar S. Shahid, M.B., B.S., M.P.H., Robert F. Breiman, M.D., and Mark C. Steinhoff, M.D.





## Implementing the National Vaccine Plan





- Defining actions
- Measuring outcomes
- Documenting progress
- Identifying barriers





#### Next Steps with National Vaccine Plan: Development of an Implementation Plan

Development of an Implementation Plan in 2011

- Includes stakeholder input
- Focused on 10 priorities
- Identifies barriers
- Provides indicators that will be used for measuring progress
  - Short-term (1-3 years)
  - Mid-term (4-9 years)
  - Long-term (10 years)
  - Aspirational





### Planned Stakeholder Engagement Efforts in 2011

- Goal is to engage stakeholders on development of an Implementation Plan plan
- Working at both national and regional levels
- Target audiences
  - Stakeholder organizations, including cbos
  - Regional and local public health
  - Faith-based organizations





## Implementation Questions for Consideration by Stakeholders

- National Vaccine Plan Measuring Progress
  - How should we measure the overall progress in meeting the goals and objectives of the National Vaccine Plan?
  - How can progress in addressing the goals of the National Vaccine Plan (including that of the non-Fed stakeholders) best be captured and shared broadly?

#### Priorities

- What actions can partners (national, state, Tribal, local, and Territorial governments, non-profit, and private) take to address the goals and priorities in the National Vaccine Plan?
- Are there additional priorities that should be included in the Implementation Plan?

#### Barriers

- What are the barriers to achieving these priorities?
- What can the government and partners do to address these barriers?





### National Vaccine Plan Implementation: Role for NVAC

- Helping to ensure that recommendations are framed within the goals of National Vaccine Plan
- Annual report on progress in meeting National Vaccine Plan goals and objectives presented at NVAC meeting.
- Report will include summary of progress, identify areas where is lagging, and propose alternative approaches where needed.
- Mid-course review





	Federal																
						HHS	;										
Objective	ACF	AHRQ	ASPR (BARDA)	CDC	CMS	FDA	HRSA	SE	HIN	NVPO	ONC	SHO	DoD	DoJ	Dept. of State	USAID	VA
	Goal	1: De	velop	new a	nd im	prove	ed vac	cines									
1.1			~	<b>-</b>		~		~	~	~			~			~	<b>✓</b>
1.2			<b>-</b>	<b>'</b>		~			<b>-</b>				~			~	· /
1.3 1.4			~	<u> </u>		_			~							-	<u> </u>
1.4				~		Ť			~	_		_	Ž			-	<u> </u>
1.6				~		~			~				~				~
	Goal 2: Enhance the vaccine safety system																
2.1				~		~	~		~	<b>-</b>			~				· ·
2.2						~							~				
2.3				<b>~</b>	~	~	<b>'</b>	~		<b>'</b>			~				<u> </u>
2.4			~	<u> </u>	· /	· /	~	· /									· · ·
2.5 2.6				-	Ť	-	-	-	_	Ť			-				-
2.7				~	~	~		~		~			-				~
2.8		~		~	~	~	~			~			~			~	~
	Goal	3: Su	pport	comm	unica	tions	to enh	nance	inforn	ned va	ccine	decis	ion-m	aking			
3.1	~			_	~	~		~	~	~			~				<b>✓</b>
3.2	~			~	~	~	~	~	~	~			~				~
3.3	<b>-</b>			<b>'</b>		<b>'</b>	<b>'</b>	<b>'</b>	<b>-</b>	<b>'</b>			_				· /
3.4 3.5				<u> </u>	<u> </u>		<u> </u>		<u> </u>	<u> </u>			- <u>-</u>			_	<u> </u>
		4: En	sure a								of rec	omm		d vacc	ines i	n the l	Jnited States
4.1			<u> </u>			· / ·	~	~					~	I	T	T	✓ ×
4.2			~	-	~		-	-		-			-			~	~
4.3				<b>-</b>	~			~								~	<b>√</b>
4.4				<b>'</b>	~		<b>'</b>	<b>'</b>			~		~			<b>'</b>	<b>~</b>
4.5				<u> </u>	<u> </u>	<b>Y</b>	<u> </u>	· /		_							<u> </u>
4.6 4.7			~	~	Ť	~	~	-		~				<del>                                     </del>	<del>                                     </del>	<u> </u>	·
4.8	~		~	~			~	-				~	~	~			~
4.9	~			<b>~</b>									~		~	~	✓
	Goal	5: Inc	crease	global	prev	entio	n of de	ath a	nd dise	ease th	roug	h safe	and e	effecti	ve vac	cinati	on
5.1				<b>~</b>					~				~		~	~	
5.2				<b>'</b>									~		<b>'</b>	<b>'</b>	
5.3				<u> </u>		~			~								
5.4 5.5			_	~		~									~	Ť	
5.6				-		-			_				_		-	-	

									Fe	deral							
						HHS	;										
Objective	ACF	AHRQ	ASPR (BARDA)	כמכ	CMS	FDA	HRSA	IHS	HIN	NVPO	ONC	SHO	ОоО	DoJ	Dept. of State	USAID	NA NA
	Go.	1: De	velop	new a	nd im	prove	ed vac	cines									
1.1				<b>V</b>		<b>~</b>		~	<b>~</b>	<b>~</b>			~			-	~
1.2			<u> </u>	· /		_										<u> </u>	· ·
1.3 1.4			~	~		~			-				~	<del>                                     </del>	<del>                                     </del>	Ť	· ·
1.5			~	~					~	~		~	~			~	
1.6				<b>~</b>		<b>✓</b>			<b>✓</b>				<b>~</b>				<b>✓</b>
	Goal 2: Enhance the vaccine safety system																
2.1				~		<b>Y</b>	~		~	~			<b>'</b>				~
2.2				_	_	✓ ✓	_	_		_			<u> </u>				_
2.4			_	~	~	~	~	-		~			-				· ·
2.5				<b>✓</b>	~	~	~	~		~			~				✓
2.6				<b>~</b>		~	<b>✓</b>	~	<b>✓</b>				~				✓
2.7 2.8		~		<b>-</b>	<u> </u>	<u> </u>	_	~		<u> </u>			<u> </u>			-	<u> </u>
2.0	Goal		pport	comm				nance	inform		ccine	decis		aking			-
3.1	<u> </u>	3.30	ррогс		~	<u> </u>	10 0111		····	- V	Cemic	l decis			Ī	T	_
3.2	~			~	~	~	~	~	~	~			~				V
3.3	<b>✓</b>			<b>~</b>	~	~	~	~	~	✓			~				<b>√</b>
3.4 3.5	<u> </u>			<u> </u>	<u> </u>	<u> </u>	<u> </u>			<u> </u>			<u> </u>				· ·
3.3		4. En	suro a								of roc	omm		d vacc	inos ir	a tha I	United States
4.1	Goal	4. En		Stable	supp	viy Oi,	access 	\ ✓	a bett	er use	or rec		-	l vacc	ines II	Tile (	✓ ✓
4.2			~	~	~		~	~		~			~			~	~
4.3				~	<b>✓</b>			~								~	<b>✓</b>
4.4				<b>Y</b>	<b>-</b>		<b>/</b>	<b>/</b>			~		<b>Y</b>			<b>/</b>	<u> </u>
4.5 4.6				<b>~</b>	~	✓ ✓	· /	✓ ✓	~	_			~				· ·
4.7			~	~		~	~	~		~							
4.8	~		<b>✓</b>	<b>~</b>			~	~				~	<b>~</b>	~			✓
4.9	<b>~</b>			~									<b>/</b>				<b>✓</b>
	Goal	5: Inc	crease	global	prev	entio	n of de	ath a		ease th	roug	h safe	_	effecti			on
5.1				<b>Y</b>					~				<b>Y</b>		<b>'</b>	<b>Y</b>	
5.2 5.3				<u> </u>		~			_				~		~		
5.4				~		-									~	~	
5.5			~	~		~									~	~	
5.6				<b>✓</b>		~			<b>✓</b>				<b>✓</b>		<b>✓</b>	<b>✓</b>	

					Non-f	ederal									
Objective	Health care providers	Health care system	Public and private health care plans	State, local, and tribal governments	Academia	Advocacy organizations	Philanthropic organizations	Vaccine manufacturers	UNICEF	WHO					
	Goal 1: De	evelop nev	w and impro	oved vaccin	es										
1.1	~			~	<b>~</b>		~	~		<b>✓</b>					
1.2					·		·	~							
1.3					<b>*</b>		<b>-</b>	<b>-</b>							
1.5					<u> </u>		· /	-/							
1.6								-							
	Goal 2: Enhance the vaccine safety system														
2.1				_	<b>/</b>	~		~							
2.2					<b>✓</b>			~							
2.3		<b>~</b>	<b>~</b>	<u> </u>	<b>~</b>			~							
2.5		<u> </u>	<u> </u>	<u> </u>	<u> </u>			· /							
2.6		•	•	•	~			~							
2.7		~	<b>~</b>	~	<b>~</b>			~							
2.8			<b>✓</b>		<b>✓</b>			~		✓					
	Goal 3: Su	upport con	nmunicatio	ns to enhar	nce informe	ed vaccine o	decision-m	naking							
3.1		~	<b>✓</b>	~	<b>✓</b>			~							
3.2	~	~	<b>~</b>	~	~	~		~							
3.3 3.4	<u> </u>	<b>~</b>	<b>~</b>	<b>~</b>	<b>✓</b>	·		~							
3.5	~	<u> </u>	<u> </u>		~	<u> </u>									
	Goal 4: Fr						ommende		es in the	United States					
4.1	~	~		<u> </u>				_	T						
4.2	~			~				~							
4.3		<b>~</b>	<b>~</b>	~				~							
4.4 4.5	~	<b>~</b>	<b>~</b>	<u> </u>	~	~	<b>~</b>	<b>-</b>							
4.6		<u> </u>	~	<u> </u>			~	<b>-</b>							
4.7	~	~			~	~		~							
4.8		-	_			~	~	~							
4.9	~	<b>✓</b>	<b>✓</b>	<b>✓</b>				<b>✓</b>							
	Goal 5: In	crease glo	bal prevent	ion of deat	h and disea	se through	safe and	effective	vaccinati	ion					
5.1					<b>✓</b>	~	<b>/</b>		~	<b>✓</b>					
5.2					~	~	·		~	<b>✓</b>					
5.3 5.4					<b>~</b>	<b>-</b>	1		<b>'</b>	<b>*</b>					
5.5					<u> </u>	<u> </u>	~			✓ ✓					
5.6					~	~	~			~					

					Non-f	ederal									
Objective	Health care provide ''s	Health care system	Public and private health care plans	State, local, and tribal governments	Academia	Advocacy organizations	Philanthropic organizations	Vaccine manufacturers	UNICEF	МНО					
	Goal 1.	evelop ne	w and impr	oved vaccin	ies										
1.1	~			<b>~</b>	<b>~</b>		<b>/</b>	~		~					
1.2					~		~								
1.3					~		~	<u> </u>							
1.5					~		~	~							
1.6					<b>~</b>			<b>-</b>							
	Goal 2: Enhance the vaccine safety system														
2.1				~	~	~		~							
2.2					<b>✓</b>			~							
2.3		~	<b>~</b>	<b>~</b>	<b>~</b>			~							
2.5		<u> </u>	~	<u> </u>	<u> </u>			<b>✓</b>							
2.6		•	v	•	~			~							
2.7		~	<b>✓</b>	<b>✓</b>	<b>✓</b>			~							
2.8			<b>✓</b>		<b>✓</b>			<b>✓</b>		✓					
	Goal 3: St	upport con	nmunicatio	ns to enhar	nce informe	ed vaccine o	decision-m	naking							
3.1		~	~	~	~			~							
3.2	~	~	<b>✓</b>	~	<b>✓</b>	✓		<b>✓</b>							
3.3 3.4	~	~	<b>~</b>	<b>~</b>	~	<b>✓</b>		<b>~</b>							
3.5	~	<u> </u>	<u> </u>	<u> </u>	_	<u> </u>		<u> </u>							
	Goal 4: Er						ommondo		as in the	United States					
4.1	G0al 4: El	v	v v	v v	and better	use of fect	Jimmenide		- mille	officed States					
4.2	~	~	~	~				<u> </u>							
4.3		<b>✓</b>	<b>✓</b>	<b>✓</b>				~							
4.4	~	~	~	~	~	~	~	~							
4.5 4.6		~	~	~			~	~							
4.7	~	<b>-</b>		<u> </u>	<u> </u>	-		<u> </u>							
4.8		~	_	~	· ·	~	_	~							
4.9	~	~	~					~							
	Goal 5: In	crease glo	bal prevent	tion of deat	h and disea	se through	safe and	effective	vaccinati	ion					
5.1					<b>✓</b>	✓ ×	_		_	<b>✓</b>					
5.2					~	~	~		~	<b>✓</b>					
5.3 5.4					<b>✓</b>	<b>✓</b>	<b>~</b>		~	✓					
5.5					<b>*</b>	<b>-</b>	<b>-</b>		~	<b>*</b>					
5.6					<u> </u>		<u> </u>	<b>✓</b>	_	<u> </u>					

	Federal															Non-federal											
						HHS														_							
Objective	ACF	AHRQ	ASPR (BARDA)	CDC	CMS	FDA	HRSA	IHS	HIN	NVPO	ONC	DHS	DoD	DoJ	Dept. of State	USAID	VA	Health care providers	Health care system	Public and private health care plans	State, local, and tribal governments	Academia	Advocacy organizations	Philanthropic organizations	Vaccine manufacturers	UNICEF	мно
	Goal 1: Develop new and improved vaccines														Goal 1: D	evelop ne	w and impr	oved vaccir	nes								
1.1			✓	✓		✓		✓	✓	✓			✓			✓	√	✓			✓	✓		✓	✓		✓
1.2			<b>V</b>	✓		✓			✓				<b>V</b>			<b>V</b>	√					<b>√</b>		✓	✓		
1.3			✓	<b>√</b>					<b>√</b>				<b>√</b>			✓	√ /					✓		✓	✓		
1.4			1	<b>√</b>		✓			<b>√</b>	<b>√</b>		1	<b>√</b>			<b>√</b>	✓					1		<b>√</b>	<b>√</b>		
1.5 1.6			٧	<b>✓</b>		1			✓ ✓	V		✓	· /				_					<b>√</b>		✓	<b>√</b>		
	Goal	2: Enl	hance	-	ccine		y syste	m	,								<u> </u>	Goal 2: E	nhance th	e vaccine sa	fety system				,		
2.1				✓		✓	✓		✓	✓			✓				√				✓	✓	✓		✓		
2.2						✓							✓									✓			✓		
2.3	_			✓	✓	✓	✓	✓		✓			✓				✓		✓	✓	✓	✓			✓		
2.4	_	_	<b>√</b>	<b>√</b>	√ ✓	<b>V</b>	<b>√</b>	<b>√</b>		√ √			√ √				<b>√</b>		<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>			1		
2.5 2.6	-	$\rightarrow$		<b>√</b>	· ·	<b>√</b>	<b>√</b>	<b>✓</b>	1	· ·			· /				<b>√</b>		✓	✓	√	<b>√</b>			√ √		
2.7	_	_		<b>√</b>	1	<i>-</i>	•	<b>√</b>	•	1			<i>\</i>				<b>√</b>		<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>			<b>√</b>		
2.8		<b>√</b>		<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>			<b>√</b>			<b>√</b>			<b>√</b>	<b>√</b>			· /	-	· ·			<i>-</i>		<b>√</b>
	Goal	3: Su	pport o	omm	unica	tions	to enh	ance	inform	ned va	ccine	decisi	on-m	aking				Goal 3: Support communications to enhance informed vaccine decision-making									
3.1	<b>√</b>			✓	✓	✓		✓	✓	✓			✓				✓		✓	✓	✓	✓			✓		
3.2	<b>V</b>	$\rightarrow$		<b>√</b>			<b>√</b>				<b>√</b>		<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>		<b>V</b>								
3.3	<b>√</b>	-		<b>√</b>	√ √	<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>	√ √			<b>√</b>				<b>√</b>		<b>√</b>	✓	<b>√</b>	✓	<b>√</b>		<b>√</b>		
3.4 3.5	<b>✓</b>			<b>√</b>	<b>√</b>	<b>∀</b>	<b>√</b>	<b>∨</b>	✓ ✓	<b>√</b>			<b>√</b>				<b>✓</b>		✓ ✓	<b>√</b>	√ √	<b>√</b>	<b>√</b>		√ √		
	_	4: En	sure a	stable							of rec	omm		vacc	ines ir	the l	United States	Goal 4: F						ommende		es in the	United States
4.1		1	✓ I	<u>√</u>		., o., ·	<b>√</b>	<b>√</b>		✓			✓ I				✓	√ V	√ √	✓	√ √	Janu Dette	. asc of fee	- Inneriae	√ vacciii	- January	J.Ateu States
4.2			·	·	<b>√</b>		·	·		<i>\</i>			·			<b>√</b>	·	· /	<b>✓</b>	<b>✓</b>	<b>✓</b>				V		
4.3				✓	✓			✓								✓	✓		✓	✓	✓				1		
4.4				✓	✓		✓	✓			✓		✓			✓	✓	✓	✓	✓	✓	✓	✓	✓	✓		
4.5				<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>	✓				<b>V</b>			<b>√</b>	<b>√</b>		✓	✓	✓			✓	<b>√</b>		
4.6	_	_	<b>√</b>	1	✓	<b>√</b>	<b>√</b>	<b>√</b>		<b>√</b>			<b>√</b>			✓	✓		1		1	1	1		1		
4.7 4.8	<b>✓</b>		V /	<b>√</b>		¥	<b>✓</b>	<b>✓</b>		· ·		1	1	1			<b>√</b>		✓ ✓	1	√ √	V	✓ ✓	-/	✓ ✓		
4.8	<u> </u>		-	<b>√</b>									<b>V</b>	•	<b>√</b>	<b>√</b>	<b>√</b>		<b>✓</b>	1	<b>√</b>		V	٧	<b>√</b>		
	_	5: Inc	rease g	global	preve	entior	n of de	ath a	nd dise	ease th	roug	h safe	and e	ffectiv	ve vac	cinati	on			bal preven		th and disea	ase throug	h safe and		vaccinat	ion
5.1				✓					1				✓		✓	✓						✓	✓	✓		<b>√</b>	✓
5.2				✓									✓		✓	✓						✓	✓	✓		✓	✓
5.3				<b>√</b>		✓			✓						<b>√</b>	✓						✓	✓	✓		✓	✓
5.4		_		<b>√</b>											<b>√</b>	1						✓	<b>1</b>	✓		✓	<b>√</b>
5.5 5.6			✓	<b>√</b>		<b>√</b>			<b>√</b>				<b>√</b>		<b>√</b>	<b>√</b>						1	√ √	1	✓		√ √

# The 2010 National Vaccine Plan







## The 2010 National Vaccine Plan







